Avances terapéuticos en el cáncer pancreático localizado

Bibliografía

1. Rahib  L, Smith  BD, Aizenberg  R, Rosenzweig  AB, Fleshman  JM, Matrisian  LM.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921.
2. National Cancer Institute. SEER stat fact sheets: pancreas cancer.http://seer.cancer.gov.libproxy1.usc.edu/statfacts/html/pancreas.html. Published October 30, 2013. Accessed May 12, 2016.
3. Winter  JM, Brennan  MF, Tang  LH,  et al.  Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19(1):169-175.
4. Sohal  DP, Walsh  RM, Ramanathan  RK, Khorana  AA.  Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106(3):dju011.
5. Iacobuzio-Donahue  CA, Fu  B, Yachida  S,  et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806-1813.
6. Gnerlich  JL, Luka  SR, Deshpande  AD,  et al.  Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147(8):753-760.
7. Rhim  AD, Mirek  ET, Aiello  NM,  et al.  EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349-361.
8. Tuveson  DA, Neoptolemos  JP.  Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148(1-2):21-23.
9. Heestand  GM, Murphy  JD, Lowy  AM.  Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770-1778.
10. Evans  DB, George  B, Tsai  S.  Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22(11):3409-3413.
11. Appel  BL, Tolat  P, Evans  DB, Tsai  S.  Current staging systems for pancreatic cancer. Cancer J. 2012;18(6):539-549.
12. Tempero  MA, Malafa  MP, Behrman  SW,  et al.  Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083-1093.
13. Evans  DB, Farnell  MB, Lillemoe  KD, Vollmer  C  Jr, Strasberg  SM, Schulick  RD.  Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1736-1744.
14. Tran Cao  HS, Balachandran  A, Wang  H,  et al.  Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269-278.
15. Raman  SP, Horton  KM, Fishman  EK.  Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012;18(6):511-522.
16. Casadei  R, Di Marco  M, Ricci  C,  et al.  Neoadjuvant chemoradiotherapy and surgery vs surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802-1812.
17. Golcher  H, Brunner  TB, Witzigmann  H,  et al.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7-16.
18. Glant  JA, Waters  JA, House  MG,  et al.  Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607-616.
19. Oettle  H, Post  S, Neuhaus  P,  et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.
20. Kalser  MH, Ellenberg  SS.  Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903.
21. Neoptolemos  JP, Stocken  DD, Friess  H,  et al; European Study Group for Pancreatic Cancer.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
22. Klinkenbijl  JH, Jeekel  J, Sahmoud  T,  et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776-782.
23. Swanson  RS, Pezzi  CM, Mallin  K, Loomis  AM, Winchester  DP.  The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base. Ann Surg Oncol. 2014;21(13):4059-4067.
24. Winter  JM, Cameron  JL, Campbell  KA,  et al.  1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199-1210; discussion 1210-1211. 
25. Oettle  H, Neuhaus  P, Hochhaus  A,  et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-1481.
26. Mayo  SC, Gilson  MM, Herman  JM,  et al.  Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33-45.
27. Evans  DB, Varadhachary  GR, Crane  CH,  et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496-3502.
28. Varadhachary  GR, Wolff  RA, Crane  CH,  et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487-3495.
29. Miura  JT, Krepline  AN, George  B,  et al.  Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. 2015;158(6):1545-1555.
30. Christians  KK, Tsai  S, Mahmoud  A,  et al.  Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266-274.
31. Takahashi  H, Ogawa  H, Ohigashi  H, &nb